Methods and Compositions for Targeting Tumor Microenvironment and for preventing Metastasis
AssigneesInstitut National de la Sante et da la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Universite Nice Sophia Antipolis
InventorsCedric GAGGIOLI, Guerrino MENEGUZZI, Jean ALBRENGUES
Life of this patent
Estimating the term…
Abstract
The invention relates to the invention relates to methods and compositions for targeting tumor microenvironment (TME) and for preventing metastasis. The invention also relates to methods and compositions for inhibiting the pro-invasive stromal fibroblast activity as well as the pro-invasive stromal fibroblast activation in a patient in need thereof such as a patient affected with a solid cancer.
Claims17
A method of treating or preventing metastasis in a patient affected with a Leukemia Inhibitory Factor (LIF)-expressing solid cancer, comprising administering to the patient a therapeutically effective amount of an inhibitor of the Janus Kinase 1 (JAK1)/Signal Transducer and Activator of Transcription 3 (STAT3) signalling pathway.
A method of inhibiting the pro-invasive stromal fibroblast activity of carcinoma-associated fibroblasts (CAFs) in a patient affected with a LIF-expressing solid cancer, comprising administering to the patient a therapeutically effective amount of an inhibitor of the JAK1/STAT3-signalling pathway.
A method of inhibiting the pro-invasive stromal fibroblast activation of carcinoma-associated fibroblasts (CAFs) in a patient affected with a LIF-expressing solid cancer, comprising administering to the patient a therapeutically effective amount of a LIF antagonist.
A method for determining whether a patient is likely to benefit from a therapy with an inhibitor of the JAK1/STAT3 signalling pathway and/or a LIF antagonist, comprising a step of (i) determining an expression level of LIF in a biological sample obtained from said patient, and (ii) comparing said expression level with a predetermined reference value, wherein an increase in expression level of the LIF gene is indicative of metastasis or of a risk of metastasis, and that the patient is thus likely to benefit form the therapy.
A method of treating recessive dystrophic epidermolysis bullosa (RDEB) in a patient in need thereof, comprising administering to the subject a therapeutically effective amount of an inhibitor of the JAK1/STAT3 signalling pathway and/or a LIF antagonist.
A pharmaceutical composition or a kit-of-parts composition comprising one or more of an inhibitor of the JAK1/STAT3 signalling pathway, a LIF antagonist and a DNA methyltransferase (DNMT) inhibitor.
16-18. (canceled)
Dependencies are inferred from the claim text.